How Mesenchymal Stem Cells Affect CD4+ T Cells in Immune Diseases
Author Information
Author(s): Lin Zehua, Cai Weisong, Sun Yuechen, Han Baoai, Hu Yifan, He Zuhong, Chen Xiong
Primary Institution: Zhongnan Hospital of Wuhan University
Hypothesis
This study aims to provide a comprehensive overview of how MSCs and their secreted extracellular vesicles (EVs) modulate CD4+T cells in immune diseases.
Conclusion
Understanding how MSCs and their EVs control CD4+T cells can offer valuable perspectives for developing innovative immunotherapeutic approaches.
Supporting Evidence
- MSCs can inhibit the activation and proliferation of CD4+T cells.
- MSCs and their EVs can effectively reduce the production of inflammatory factors.
- MSCs have shown promise in treating various immune diseases, including systemic lupus erythematosus and rheumatoid arthritis.
- MSCs can promote the differentiation of T cells into regulatory T cells.
- MSCs derived from different sources may have varying effects on immune regulation.
Takeaway
Mesenchymal stem cells can help treat immune diseases by changing how certain immune cells work, which might help people feel better.
Methodology
The study discusses the immunomodulatory properties of MSCs and explores their interactions with CD4+T cells through various pathways.
Potential Biases
The heterogeneity and safety concerns associated with MSCs limit their application.
Limitations
The inconsistent regulation of CD4+T cell subsets by MSCs may be attributed to the different sources of MSCs used in various studies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website